Manages elevated serum phosphorus levels. Sold as Fosrenol. Every FDA application for this active ingredient: 2 branded and 4 generic.
As of Nov 16, 2026, FDA lists 6 applications for Lanthanum Carbonate (sold as Fosrenol), first approved Oct 26, 2004, with 0 new uses approved and 0 published complete response letters.
| Lanthanum Carbonate | Part D | $309K | -99% | 243 |
| Fosrenol | Part D | $22K | -100% | 16 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Tenapanor in Maintenance Hemodialysis PatientsHyperphosphatemia, Maintenance Hemodialysis · Huashan Hospital | — | Not yet recruiting | Oct 20, 2026 |
| Oct 26, 2004 | FosrenolNDA 21468 · New molecular entity | Takeda Pharms USA | 16 | Marketed |
| Sep 24, 2014 | FosrenolNDA 204734 · New dosage form | Takeda Pharms USA | 6 | Marketed |
| Aug 11, 2017 | Lanthanum CarbonateANDA 90978 | Natco Pharma Ltd | 2 | Marketed |
| Jan 24, 2022 | Lanthanum CarbonateANDA 206868 | Invagen Pharms | 2 | Marketed |
| Jan 27, 2022 | Lanthanum CarbonateANDA 90977 | Barr | 3 | Marketed |
| Mar 13, 2025 | Lanthanum CarbonateANDA 202329 | Alkem Labs Ltd | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA